BMY - Bristol-Myers Squibb Co Stock Price, Fair Value and News

43.65USD-0.39 (-0.89%)Delayed as of 08 May 2024, 12:55 pm ET

Market Summary

USD43.65-0.39

Delayedas of 08 May 2024, 12:55 pm

-0.89%

BMY Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

BMY Stock Price

View Fullscreen

BMY RSI Chart

BMY Valuation

Market Cap

89.2B

Price/Earnings (Trailing)

-12.42

Price/Sales (Trailing)

1.96

EV/EBITDA

32.21

Price/Free Cashflow

7.13

BMY Price/Sales (Trailing)

BMY Profitability

EBT Margin

-12.84%

Return on Equity

-36.58%

Return on Assets

-6.11%

Free Cashflow Yield

14.02%

BMY Fundamentals

BMY Revenue

Revenue (TTM)

45.5B

Rev. Growth (Yr)

4.66%

Rev. Growth (Qtr)

3.38%

BMY Earnings

Earnings (TTM)

-6.1B

Earnings Growth (Yr)

-626.57%

Earnings Growth (Qtr)

-525.93%

Breaking Down BMY Revenue

52 Week Range

43.6569.10

(Low)(High)

Last 7 days

0.2%

Last 30 days

-14.2%

Last 90 days

-9.5%

Trailing 12 Months

-35.7%

How does BMY drawdown profile look like?

BMY Financial Health

Current Ratio

1.11

Debt/Equity

2.99

Debt/Cashflow

0.28

BMY Investor Care

Dividend Yield

4.01%

Dividend/Share (TTM)

1.96

Buy Backs (1Y)

3.51%

Diluted EPS (TTM)

-3.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	45.5B	0	0	0
2023	45.8B	45.2B	44.9B	45.0B
2022	47.0B	47.1B	46.7B	46.2B
2021	42.8B	44.4B	45.5B	46.4B
2020	31.0B	34.9B	39.4B	42.5B
2019	23.3B	23.9B	24.2B	26.1B
2018	21.0B	21.6B	22.0B	22.6B
2017	20.0B	20.2B	20.6B	20.8B
2016	16.9B	17.6B	18.5B	19.4B
2015	16.1B	16.4B	16.5B	16.6B
2014	16.4B	16.2B	16.1B	15.9B
2013	16.2B	15.8B	16.1B	16.4B
2012	21.5B	20.5B	18.9B	17.6B
2011	19.7B	20.4B	20.9B	21.2B
2010	19.3B	19.4B	19.4B	19.5B
2009	17.1B	16.6B	16.1B	18.8B
2008	0	16.3B	17.0B	17.7B
2007	0	0	0	15.6B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Bristol-Myers Squibb Co

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	shanahan karin	acquired	-	-	3,306	evp, glob. prod. dev. & supply
Apr 01, 2024	shanahan karin	sold (taxes)	-63,376	52.99	-1,196	evp, glob. prod. dev. & supply
Mar 10, 2024	hoch lynelle	acquired	-	-	4,351	president, cell therapy org.
Mar 10, 2024	elkins david v	acquired	-	-	64,326	evp, chief financial officer
Mar 10, 2024	hirawat samit	sold	-	-	-11,705	evp,chief med.offr.,drug dev.
Mar 10, 2024	caforio giovanni	sold	-	-	-57,536	executive chair of the board
Mar 10, 2024	hoch lynelle	sold (taxes)	-70,357	53.79	-1,308	president, cell therapy org.
Mar 10, 2024	plenge robert m	sold (taxes)	-105,697	53.79	-1,965	evp, chief research officer
Mar 10, 2024	gallman cari	sold (taxes)	-37,437	53.79	-696	evp, corporate affairs
Mar 10, 2024	leung sandra	sold (taxes)	-896,141	53.79	-16,660	evp, general counsel

Which funds bought or sold BMY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Merit Financial Group, LLC	added	94.83	688,680	1,716,120	0.04%
May 06, 2024	AIA Group Ltd	added	56.8	1,887,530	4,759,660	0.16%
May 06, 2024	Roof Eidam Maycock Peralta, LLC	unchanged	-	16,352	303,688	0.08%
May 06, 2024	Metis Global Partners, LLC	reduced	-1.89	226,142	6,344,910	0.23%
May 06, 2024	CAPITAL CITY TRUST CO/FL	added	0.14	74,007	1,342,140	0.37%
May 06, 2024	LMCG INVESTMENTS, LLC	reduced	-8.57	-13,547	388,775	0.02%
May 06, 2024	Carnegie Capital Asset Management, LLC	reduced	-32.91	-1,167,060	2,844,140	0.09%
May 06, 2024	Summit Asset Management, LLC	reduced	-6.53	-5,283	430,749	0.09%
May 06, 2024	Ifrah Financial Services, Inc.	reduced	-40.64	-210,219	353,827	0.10%
May 06, 2024	Sciencast Management LP	sold off	-100	-1,558,950	-	-%

Are Funds Buying or Selling BMY?

Are funds buying BMY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BMY

No. of Funds

Unveiling Bristol-Myers Squibb Co's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.74%	198,155,594	SC 13G/A
Jan 25, 2024	blackrock inc.	8.3%	168,098,227	SC 13G/A
Feb 09, 2023	vanguard group inc	9.54%	202,927,620	SC 13G/A
Feb 07, 2023	blackrock inc.	8.1%	172,720,377	SC 13G/A
Feb 09, 2022	vanguard group inc	9.00%	199,834,483	SC 13G/A
Feb 01, 2022	blackrock inc.	7.6%	169,226,706	SC 13G/A
Feb 10, 2021	vanguard group inc	8.82%	199,340,458	SC 13G/A
Jan 29, 2021	blackrock inc.	7.6%	172,464,804	SC 13G/A
Feb 12, 2020	vanguard group inc	8.32%	194,860,154	SC 13G/A
Feb 05, 2020	blackrock inc.	7.3%	171,343,446	SC 13G/A

Recent SEC filings of Bristol-Myers Squibb Co

View All Filings

Date Filed	Form Type	Document
May 03, 2024	4	Insider Trading
Apr 25, 2024	10-Q	Quarterly Report
Apr 25, 2024	8-K	Current Report
Apr 22, 2024	DEFA14A	DEFA14A
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to Bristol-Myers Squibb Co)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.6B	-2.43%	-8.39%	9.3	4.18	5.68%	202.39%
MRK	330.2B	61.4B	1.86%	10.13%	143.19	5.38	6.11%	-82.30%
AMGN	161.1B	29.5B	11.28%	28.04%	42.82	5.46	12.76%	-52.47%
PFE	156.8B	46.5B	4.16%	-28.19%	-112.94	3.37	42.59%	-114.62%
GILD	81.5B	27.1B	-5.96%	-16.75%	14.39	3.01	-0.60%	23.36%
TEVA	15.6B	15.8B	-2.04%	54.08%	-27.14	0.99	6.17%	76.47%
MID-CAP
ALKS	4.2B	1.7B	-5.86%	-20.45%	9.58	2.41	54.01%	364.56%
PRGO	4.1B	4.6B	-3.95%	-16.22%	-533.77	0.9	-0.06%	94.55%
BHC	2.7B	9.0B	-28.82%	23.71%	-5.97	0.3	10.01%	-27.45%
AMPH	2.1B	644.4M	2.42%	17.52%	14.96	3.19	29.14%	50.51%
SMALL-CAP
TLRY	1.5B	743.2M	-23.46%	-28.42%	-4.38	2.07	24.65%	80.36%
TXMD	23.2M	1.3M	-9.05%	-48.20%	-2.26	17.8	-98.14%	-109.18%
ACRX	17.0M	-	-15.25%	35.14%	-0.92	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	31.03%	-94.02%	-0.19	0.14	80.00%	43.08%
ACOR	1.1M	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

Bristol-Myers Squibb Co News

Latest updates

Bristol-Myers Squibb Co Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	3.4%	11,865	11,477	10,966	11,226	11,337	11,406	11,218	11,887	11,648	11,985	11,624	11,703	11,073	11,068	10,540	10,129	10,781	7,945	6,007	6,273	5,920
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,158	8,038	7,430	7,119	5,453	4,217	4,301	4,096
Costs and Expenses	138.5%	23,381	9,803	8,829	9,367	8,567	9,547	9,009	9,929	9,961	10,127	9,467	10,150	8,543	21,519	8,283	8,502	11,085	8,074	4,658	4,497	3,941
S&GA Expenses	14.2%	2,367	2,073	2,003	1,934	1,762	2,266	1,930	1,787	1,831	2,354	1,788	1,882	1,666	2,721	1,706	1,628	1,606	1,734	1,055	1,076	1,006
R&D Expenses	8.8%	2,695	2,478	2,242	2,258	2,321	2,510	2,418	2,321	2,260	2,518	2,980	2,478	2,219	2,655	2,499	2,522	2,372	2,097	1,378	1,325	1,348
EBITDA Margin	-78.2%	0.09*	0.40*	0.41*	0.41*	0.41*	0.39*	0.39*	0.38*	0.38*	0.40*	0.14*	0.15*	0.15*	0.08*	0.31*	0.26*	0.22*	-	-	-	-
Income Taxes	545.5%	392	-88.00	203	-218	503	-166	601	529	404	-514	605	492	501	-424	379	1,707	462	931	-17.00	337	264
Earnings Before Taxes	-787.9%	-11,516	1,674	2,137	1,859	2,770	1,859	2,209	1,958	1,687	1,858	2,157	1,553	2,530	-10,451	2,257	1,627	-304	-129	1,349	1,776	1,979
EBT Margin	-168.5%	-0.13*	0.19*	0.19*	0.19*	0.19*	0.17*	0.17*	0.16*	0.15*	0.17*	-0.09*	-0.09*	-0.09*	-0.16*	0.09*	0.07*	0.09*	-	-	-	-
Net Income	-525.9%	-11,911	2,797	1,928	4.00	2,262	3,365	1,606	8.00	5.00	3,917	1,546	-6.00	-8.00	-10,027	1,872	-85.00	-775	-1,056	1,353	1,432	1,710
Net Income Margin	-202.1%	-0.13*	0.13*	0.10*	0.09*	0.12*	0.12*	0.15*	0.15*	0.12*	0.12*	-0.19*	-0.18*	-0.19*	-0.21*	0.00*	-0.02*	0.03*	-	-	-	-
Free Cashflow	-35.0%	2,550	3,922	4,409	1,628	2,692	2,960	3,440	1,989	3,559	3,737	4,996	2,850	3,651	3,072	2,114	4,362	3,751	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	4.1%	99,031	95,159	91,263	93,489	94,281	96,820	98,196	100,357	103,034	109,314	110,893	110,797	112,435	118,481	125,536	128,076	129,285	129,944	57,433	55,163	34,834
Current Assets	-9.8%	28,669	31,770	27,632	28,074	27,086	27,273	26,796	30,186	30,121	33,262	31,443	29,161	27,111	30,192	34,277	34,343	31,853	29,354	40,191	37,716	17,093
Cash Equivalents	-18.6%	9,330	11,464	7,514	8,372	9,048	9,325	7,957	10,960	12,579	14,316	13,879	11,397	11,321	14,973	19,860	20,362	16,246	12,820	30,489	28,404	7,335
Inventory	12.1%	2,985	2,662	2,436	2,364	2,605	2,339	2,074	2,142	2,104	2,095	2,163	2,137	1,953	2,074	1,949	2,384	2,836	4,293	1,192	1,308	1,283
Net PPE	1.6%	6,750	6,646	6,481	6,355	6,279	6,255	6,035	5,970	6,047	6,049	5,868	5,795	5,763	5,886	5,740	5,777	6,112	6,252	4,830	4,849	4,985
Goodwill	2.7%	21,738	21,169	21,147	21,163	21,162	21,149	21,112	20,446	20,500	20,502	20,519	20,529	20,524	20,547	20,517	20,578	22,452	22,488	6,513	6,533	-
Liabilities	25.6%	82,483	65,674	62,201	61,459	62,395	65,702	65,462	67,696	71,389	73,308	73,609	73,923	74,762	80,599	75,306	78,916	79,308	78,246	39,679	39,012	19,517
Current Liabilities	16.0%	25,822	22,262	23,462	20,150	19,085	21,890	18,930	20,915	22,821	21,868	21,460	18,991	17,330	19,080	20,464	23,421	19,232	18,304	10,489	9,711	8,841
Short Term Borrowings	98.5%	6,190	3,119	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	35.0%	49,487	36,653	32,137	34,656	35,078	35,056	36,966	37,107	37,450	39,605	39,677	42,503	44,505	48,336	44,614	46,106	46,105	46,150	24,390	24,433	5,635
LT Debt, Non Current	35.0%	49,487	36,653	32,137	34,656	35,078	35,056	36,966	37,107	37,450	39,605	39,677	42,503	44,505	48,336	41,364	41,853	42,844	43,387	24,390	24,433	5,635
Shareholder's Equity	-44.0%	16,490	29,430	28,998	57.00	45,140	25,503	44,956	292	43,756	60.00	22,625	66.00	43,852	60.00	50,230	49,160	49,977	43,709	17,754	16,151	15,317
Retained Earnings	-45.6%	15,640	28,766	28,218	27,449	26,568	25,503	24,675	24,217	23,948	23,820	22,625	22,168	22,204	21,281	32,414	31,565	32,671	34,474	36,555	35,870	35,109
Additional Paid-In Capital	-0.1%	45,655	45,684	44,849	45,299	45,140	45,165	44,956	44,375	43,756	44,361	44,292	44,064	43,852	44,325	44,435	44,444	43,254	43,709	2,206	2,150	2,103
Shares Outstanding	-	-	-	-	-	-	-	2,126	2,135	2,129	-	2,220	2,222	2,233	-	2,260	2,254	2,263	-	1,629	1,636	1,636
Minority Interest	5.5%	58.00	55.00	64.00	57.00	62.00	57.00	63.00	61.00	65.00	60.00	71.00	66.00	68.00	60.00	72.00	66.00	66.00	100	106	102	99.00
Float	-	-	-	-	133,499	-	-	-	164,301	-	-	-	148,383	-	-	-	132,443	-	-	-	74,102	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-33.3%	2,834	4,252	4,751	1,887	2,970	3,306	3,687	2,261	3,812	4,057	5,266	3,060	3,824	3,355	2,267	4,493	3,937	2,181	2,556	2,083	1,390
Share Based Compensation	4.7%	133	127	132	137	122	119	115	116	107	133	142	157	151	171	185	213	210	284	56.00	48.00	53.00
Cashflow From Investing	-1357.5%	-19,618	-1,346	-410	-329	-210	1,213	-2,081	-289	95.00	401	-976	180	-143	-11,812	-213	556	610	-12,179	491	715	1,060
Cashflow From Financing	1414.4%	14,644	967	-5,160	-2,173	-3,050	-3,246	-4,543	-3,520	-5,653	-3,967	-1,780	-3,182	-7,295	3,483	-2,587	-993	-1,054	-7,677	-941	18,268	-2,029
Dividend Payments	4.5%	1,212	1,160	1,191	1,197	1,196	1,145	1,154	1,150	1,185	1,099	1,090	1,099	1,108	1,021	1,016	1,021	1,017	668	671	671	669
Buy Backs	-	-	-	4,000	905	250	2,416	701	-	5,000	2,751	525	1,236	1,775	1,465	-	-	81.00	7,000	300	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BMY Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF EARNINGS - USD ($)
$ in Millions

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Total Revenues

$ 11,865

$ 11,337

Cost of products sold

^[1]

2,932

2,566

Marketing, selling and administrative

2,367

1,762

Research and development

2,695

2,321

Acquired IPRD

12,949

Amortization of acquired intangible assets

2,357

2,256

Other (income)/expense, net

(413)

Total Expenses

23,381

8,567

(Loss)/Earnings before income taxes

(11,516)

2,770

Income tax provision

392

503

Net (loss)/earnings

(11,908)

2,267

Noncontrolling interest

Net (loss)/earnings attributable to BMS

$ (11,911)

$ 2,262

(Loss)/Earnings per common share:

Basic (usd per share)

$ (5.89)

$ 1.08

Diluted (usd per share)

$ (5.89)

$ 1.07

Net product sales

Total Revenues

$ 11,559

$ 11,048

Alliance and other revenues

Total Revenues

$ 306

$ 289

[1]	Excludes amortization of acquired intangible assets

BMY Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 9,330	$ 11,464
Marketable debt securities	340	816
Receivables	10,447	10,921
Inventories	2,985	2,662
Other current assets	5,567	5,907
Total Current assets	28,669	31,770
Property, plant and equipment	6,750	6,646
Goodwill	21,738	21,169
Other intangible assets	32,760	27,072
Deferred income taxes	2,723	2,768
Marketable debt securities	367	364
Other non-current assets	6,024	5,370
Total Assets	99,031	95,159
Current liabilities:
Short-term debt obligations	6,190	3,119
Accounts payable	3,539	3,259
Other current liabilities	16,093	15,884
Total Current liabilities	25,822	22,262
Deferred income taxes	442	338
Long-term debt	49,487	36,653
Other non-current liabilities	6,732	6,421
Total Liabilities	82,483	65,674
Commitments and Contingencies
BMS Shareholders’ equity:
Preferred stock	0	0
Common stock	292	292
Capital in excess of par value of stock	45,655	45,684
Accumulated other comprehensive loss	(1,400)	(1,546)
Retained earnings	15,640	28,766
Less cost of treasury stock	(43,697)	(43,766)
Total BMS Shareholders’ equity	16,490	29,430
Noncontrolling interest	58	55
Total Equity	16,548	29,485
Total Liabilities and Equity	$ 99,031	$ 95,159

About Bristol-Myers Squibb Co

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

CEO	Dr. Giovanni Caforio M.D.
WEBSITE	bms.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	34300

Bristol-Myers Squibb Co Frequently Asked Questions

What is the ticker symbol for Bristol-Myers Squibb Co? What does BMY stand for in stocks?

BMY is the stock ticker symbol of Bristol-Myers Squibb Co. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bristol-Myers Squibb Co (BMY)?

As of Tue May 07 2024, market cap of Bristol-Myers Squibb Co is 89.21 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BMY stock?

You can check BMY's fair value in chart for subscribers.

What is the fair value of BMY stock?

You can check BMY's fair value in chart for subscribers. The fair value of Bristol-Myers Squibb Co is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bristol-Myers Squibb Co is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BMY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bristol-Myers Squibb Co a good stock to buy?

The fair value guage provides a quick view whether BMY is over valued or under valued. Whether Bristol-Myers Squibb Co is cheap or expensive depends on the assumptions which impact Bristol-Myers Squibb Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BMY.

What is Bristol-Myers Squibb Co's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, BMY's PE ratio (Price to Earnings) is -12.42 and Price to Sales (PS) ratio is 1.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BMY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bristol-Myers Squibb Co's stock?

In the past 10 years, Bristol-Myers Squibb Co has provided 0.009 (multiply by 100 for percentage) rate of return.